---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-030171"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2022-11-16T23:59:59+00:00"
generated_at: "2026-06-21T17:32:31.652494+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Bioventus warns of $185M-$205M impairment, rebate dispute; evaluating going concern

## Summary
- Preliminary review indicates a non-cash impairment charge of $185M to $205M for Q3 2022.
- Disputed rebate invoice from a large private payer in Pain Treatments likely to reduce Q3 revenue and may affect revenue guidance.
- Management concludes internal controls for quarterly rebate recognition were inadequate for period ended Oct 1, 2022.
- Evaluating ability to meet financial obligations within one year; considering mitigation steps.
- Expects to file Form 10-Q by Nov 21, 2022, using 12b-25 extension.

## SEC filing metadata
- accession: 0001628280-22-030171
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2022-11-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828022030171/0001628280-22-030171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828022030171/bvs-20221116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-030171
- JSON: https://secwatch.observer/filing/0001628280-22-030171.json
- Plain text: https://secwatch.observer/filing/0001628280-22-030171.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.